Last reviewed · How we verify
metformin, gliclazide, protaphane
At a glance
| Generic name | metformin, gliclazide, protaphane |
|---|---|
| Sponsor | Chinese University of Hong Kong |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- HbA1c Variability in Type II Diabetes (NA)
- Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes (PHASE4)
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (PHASE4)
- The Impact of Glucotoxicity on Gastric Emptying in Chinese Patients With Newly Diagnosed Type 2 Diabetes
- The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians (PHASE4)
- Association Between Insulin Resistance and Beta Cell Function With HbA1C in Diabetics
- An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)
- Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |